SCHEMBL20436366

SCHEMBL20436366

Cc1ccc2c(c1)C(C)(O)C(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
POLB P06746 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
ALOX12 P18054 1/20 0.49
ADAMTS5 Q9UNA0 3/20 0.46
MGAM O43451 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
AKR1B1 P15121 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PDK2 Q15119 1/20 0.40
PDK4 Q16654 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23972238 0.85 AKR1B1 (0.45) CYP1A2POLBCYP3A4CYP2C19ALDH1A1
SCHEMBL31238639 0.81 CYP1A2 (0.57) CYP1A2POLBCYP3A4CYP2C19GAA
SCHEMBL2265773 0.81 CYP1A2 (0.57) CYP1A2POLBCYP3A4CYP2C19GAA
SCHEMBL30132814 0.80 CYP1A2 (0.53) CYP1A2POLBCYP2C19MAPTAKR1B1
SCHEMBL3524533 0.80 LMNA (0.57) POLBCYP3A4CYP2C19ALDH1A1GAA
SCHEMBL25313851 0.80 CYP1A2 (0.53) CYP1A2POLBCYP2C19MAPTAKR1B1
SCHEMBL10116531 0.80 TGM2 (0.41) CYP1A2POLBCYP3A4CYP2C19ALDH1A1
SCHEMBL30293276 0.77 PGR (0.51) ALDH1A1GAAKDM4EAKR1B1KMT2A
SCHEMBL10116536 0.76 IDO1 (0.36) CYP1A2POLBCYP3A4CYP2C19ALDH1A1
SCHEMBL15715190 0.76 CYP1A2 (0.56) CYP1A2POLBCYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3573960-B1 N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES GENFIT (FR) 2023-08-16 EP disclosed
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 US disclosed
WO-2018138362-A1 N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES GENFIT (FR) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB CYP1A2 137/4885POLB 4176/4885CYP3A4 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.